Compare Incyte Corporation (INCY) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ServiceNow Inc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while ServiceNow Inc trades at $101.95 (market cap $107.98B). The key difference: ServiceNow Inc is far larger — about 4.7× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| INCY | NOW | |
|---|---|---|
Market Cap | $23.11B | $107.98B |
Sector | Health | Technology |
52-Week High | $118.52 | $199.24 |
52-Week Low | $67.38 | $83.00 |
Enterprise Value | $19.13B | $105.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
ServiceNow (NOW) trades at $103.24, down 0.74% today, with a bearish technical signal but strong fundamentals including 76.56% gross margins and consistent revenue growth to $13.28B in 2025. The stock shows robust cash flow generation of $5.44B from operations and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth opportunities and conference presentations.
Outlook remains positive with an 85.51% analyst buy rating and $135.14 consensus price target, suggesting 31% upside. Key risks include high valuation multiples (P/E 62.32) and competitive pressures in enterprise software. Earnings execution and AI adoption present the primary catalysts for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
